[go: up one dir, main page]

MX2022000743A - Tratamiento mejorado utilizando eyp001. - Google Patents

Tratamiento mejorado utilizando eyp001.

Info

Publication number
MX2022000743A
MX2022000743A MX2022000743A MX2022000743A MX2022000743A MX 2022000743 A MX2022000743 A MX 2022000743A MX 2022000743 A MX2022000743 A MX 2022000743A MX 2022000743 A MX2022000743 A MX 2022000743A MX 2022000743 A MX2022000743 A MX 2022000743A
Authority
MX
Mexico
Prior art keywords
eyp001
improved treatment
treatment
pruritus
decrease
Prior art date
Application number
MX2022000743A
Other languages
English (en)
Inventor
Raphaël Darteil
Jacky Vonderscher
Pietro Scalfaro
Elise Roy
Original Assignee
Enyo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enyo Pharma filed Critical Enyo Pharma
Publication of MX2022000743A publication Critical patent/MX2022000743A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un método de tratamiento con un agonista de FXR que permite disminuir el prurito y mejorar la eficacia.
MX2022000743A 2019-07-18 2020-07-17 Tratamiento mejorado utilizando eyp001. MX2022000743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19186947 2019-07-18
PCT/EP2020/070239 WO2021009331A1 (en) 2019-07-18 2020-07-17 Improved treatment using eyp001

Publications (1)

Publication Number Publication Date
MX2022000743A true MX2022000743A (es) 2022-02-14

Family

ID=67437957

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000743A MX2022000743A (es) 2019-07-18 2020-07-17 Tratamiento mejorado utilizando eyp001.

Country Status (12)

Country Link
US (1) US20220249469A1 (es)
EP (1) EP3999100B1 (es)
JP (1) JP7617898B2 (es)
KR (1) KR20220035366A (es)
CN (1) CN114025760B (es)
AU (1) AU2020312734B2 (es)
CA (1) CA3139750A1 (es)
ES (1) ES3040069T3 (es)
IL (1) IL288937A (es)
MX (1) MX2022000743A (es)
WO (1) WO2021009331A1 (es)
ZA (1) ZA202201713B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024503861A (ja) * 2021-01-14 2024-01-29 ウエヌイグレックオ・ファーマ 慢性腎疾患を処置する方法
WO2022229302A1 (en) * 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN115400141B (zh) * 2022-09-20 2023-08-11 天津医科大学总医院 Sting激动剂在制备治疗慢性瘙痒的药物中的应用
US12030861B1 (en) * 2023-07-13 2024-07-09 Enyo Pharma L-lysine salt of 4-chloro-5-[4-(2,6-dichlorophenyl)sulfonylpiperazin-1-yl]-1-benzofuran-2-carboxylic acid and various forms thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ545536A (en) * 2003-09-05 2010-04-30 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C
SI2712617T1 (sl) * 2004-03-12 2017-01-31 Intercept Pharmaceuticals, Inc. Zdravljenje fibroze z uporabo Fxr ligandov
DK3043865T3 (da) * 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
EP3842043A1 (en) * 2016-02-22 2021-06-30 Novartis AG Methods for using fxr agonists
CA3029478A1 (en) 2016-06-29 2018-01-04 Menlo Therapeutics Inc. Use of neurokinin-1 antagonists to treat a variety of pruritic conditions
CN109689050A (zh) 2016-09-14 2019-04-26 诺华股份有限公司 Fxr激动剂的新方案
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
WO2018065902A1 (en) * 2016-10-05 2018-04-12 Novartis Ag Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder
EP3562490A1 (en) * 2016-12-28 2019-11-06 Modunex Bio Corp. Combination therapy for nonalcoholic steatohepatitis (nash) and liver fibrosis
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases

Also Published As

Publication number Publication date
CA3139750A1 (en) 2021-01-21
ZA202201713B (en) 2025-06-25
CN114025760A (zh) 2022-02-08
AU2020312734A1 (en) 2022-01-20
JP7617898B2 (ja) 2025-01-20
EP3999100A1 (en) 2022-05-25
IL288937A (en) 2022-02-01
US20220249469A1 (en) 2022-08-11
EP3999100B1 (en) 2025-08-20
CN114025760B (zh) 2023-12-01
ES3040069T3 (en) 2025-10-28
WO2021009331A1 (en) 2021-01-21
AU2020312734B2 (en) 2025-11-20
JP2022542830A (ja) 2022-10-07
EP3999100C0 (en) 2025-08-20
KR20220035366A (ko) 2022-03-22

Similar Documents

Publication Publication Date Title
MX2022000743A (es) Tratamiento mejorado utilizando eyp001.
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
IL284640A (en) Pcsk9 inhibitors and methods of use thereof
IL284661A (en) Pcsk9 inhibitors and methods of use thereof
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
PH12020500655A1 (en) Compounds
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
EP3856176A4 (en) Inhibitors of vap-1
MX384205B (es) Metodos para usar agonistas de fxr.
MX2018013983A (es) Inhibidores g12c de kras.
EA202191023A2 (ru) Фунгицидные комбинации
EA201991556A1 (ru) Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
MX384240B (es) Bacterias probioticas recombinantes.
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
EA033403B1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
MY203303A (en) Compounds
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
MX2021010460A (es) Metodo de tratamiento con tradipitant.
EA201792227A1 (ru) Лечение рака легких ингибиторами глутаминазы
MX382996B (es) Inhibidores de pcna
MX2019009908A (es) Combinacion de un agonista de ppar con un agonista de fxr.